Rare Neurology News
Advertisement
Disease Profile
Ovarian carcinosarcoma
Prevalence estimates on Rare Medical Network websites are calculated based on data available from numerous sources, including US and European government statistics, the NIH, Orphanet, and published epidemiologic studies. Rare disease population data is recognized to be highly variable, and based on a wide variety of source data and methodologies, so the prevalence data on this site should be assumed to be estimated and cannot be considered to be absolutely correct.
0
Age of onset
Adult
ICD-10
C56
Inheritance
Autosomal dominant A pathogenic variant in only one gene copy in each cell is sufficient to cause an autosomal dominant disease.
Autosomal recessive Pathogenic variants in both copies of each gene of the chromosome are needed to cause an autosomal recessive disease and observe the mutant phenotype.
X-linked
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
X-linked
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
Mitochondrial or multigenic Mitochondrial genetic disorders can be caused by changes (mutations) in either the mitochondrial DNA or nuclear DNA that lead to dysfunction of the mitochondria and inadequate production of energy.
Multigenic or multifactor Inheritance involving many factors, of which at least one is genetic but none is of overwhelming importance, as in the causation of a disease by multiple genetic and environmental factors.
Not applicable
Other names (AKA)
Malignant mixed mullerian tumor of the ovary; Malignant mixed Müllerian tumor of the ovary; MMMT of the ovary;
Categories
Female Reproductive Diseases; Rare Cancers
Summary
Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive
Treatment
Currently, treatment for ovarian carcinosarcoma usually begins with surgery to remove as much of the cancer as possible.
Organizations
Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.
Organizations Supporting this Disease
-
Minnesota Ovarian Cancer Alliance
4604 Chicago Ave
Minneapolis, MN 55407
Telephone: 612-822-0500
E-mail: [email protected]
Website: https://mnovarian.org/ -
National Ovarian Cancer Coalition
2501 Oak Lawn Avenue, Suite 435
Dallas, TX 75219
Toll-free: 888-OVARIAN
Telephone: 214-273-4200
Fax: 214-273-4201
E-mail: [email protected]
Website: https://www.ovarian.org/ -
Ovarian Cancer Research Alliance
14 Pennsylvania Plaza, Suite 2110
New York, NY 10122
Toll-free: 866-399-6262
Telephone: 212-268-1002
Fax: 202-331-2292
E-mail: [email protected]
Website: https://ocrahope.org -
The Gynecological Carcinosarcoma Project (GCS Project)
2795 Estates Drive
Park City, UT 84060
E-mail: [email protected]
Website: https://gcsproject.org/ -
The Liddy Shriver Sarcoma Initiative
17 Bethea Drive
Ossining, NY 10562-1620
Telephone: 914-762-3251
Website: https://sarcomahelp.org/
Social Networking Websites
- Visit the following Facebook groups related to Ovarian carcinosarcoma:
MMMT (Malignant Mixed Mullerian Tumor) aka Carcinosarcoma
The GCS Project
Learn more
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
In-Depth Information
- The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.
- Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.
- PubMed is a searchable database of medical literature and lists journal articles that discuss Ovarian carcinosarcoma. Click on the link to view a sample search on this topic.
References
- del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecologic Oncology. 2012; 125:271-277. https://www.ncbi.nlm.nih.gov/pubmed/22155675.
- Kim HJ, Lee HM, Kim MK, Lee YK, Lee IH, Lee KH, Kim H. Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma. Obstet Gynecol Sci. July, 2017; 60(4):350-356. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547082/.
- Sonoda Y, Saigo PE, Federici MG, Boyd J. Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin. Gynecologic Oncology. 2000; 76:226-229. https://www.ncbi.nlm.nih.gov/pubmed/10637076. Accessed 3/27/2013.
- National Comprehensive Cancer Network. Ovarian Cancer. NCCN Guidelines for Patients. 2017; https://www.nccn.org/patients/guidelines/ovarian/index.html.
Rare Neurology News